Accéder au contenu
MilliporeSigma

Discovery of a novel HCV helicase inhibitor by a de novo drug design approach.

Bioorganic & medicinal chemistry letters (2009-05-06)
Sahar Kandil, Sonia Biondaro, Dimitrios Vlachakis, Anna-Claire Cummins, Antonio Coluccia, Colin Berry, Pieter Leyssen, Johan Neyts, Andrea Brancale
RÉSUMÉ

Herein we report a successful application of a computer-aided design approach to identify a novel HCV helicase inhibitor. A de novo drug design methodology was used to generate an initial set of structures that could potentially bind to a putative binding site. Further structure refinement was carried out through docking a series of focused virtual libraries. The most promising compound was synthesised and it exhibited a submicromolar inhibition of the HCV helicase.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Methyl 4-(aminomethyl)benzoate hydrochloride, 97%